Analyst firms · Wolfe Research · MDGL

Wolfe Research MDGL price target and rating history

Madrigal Pharmaceuticals Inc. (MDGL) · Health Care

Wolfe Research rates Madrigal Pharmaceuticals Inc. (MDGL) Outperform with a $605 price target, as of its latest action on Aug 4, 2026. It has published 3 rating actions on MDGL since June 2024, including 1 upgrade and 1 downgrade. Across 5 firms with a MDGL price target in the last 12 months, the median target is $704. Wolfe Research's $605 is 14% below that.

Current rating

Outperform

Price target

$605

Median target, all firms

$704

Actions on MDGL

3

Wolfe Research price target on MDGL

Every Wolfe Research rating on MDGL

• Aug 4, 2026
  UpgradeWolfe Research upgrades to Outperform from Peer Perform, price target $605
• Jan 6, 2026
  DowngradeWolfe Research downgrades to Peer Perform from Outperform
• Jun 11, 2024
  InitiateWolfe Research starts coverage at Outperform, price target $382

How other firms rate MDGL

Each firm's latest rating and stated target in the last 12 months.

Questions about Wolfe Research and MDGL

What is Wolfe Research's price target for MDGL?

Wolfe Research's latest stated price target for Madrigal Pharmaceuticals Inc. (MDGL) is $605, from its action on Aug 4, 2026.

What is Wolfe Research's rating on MDGL?

Wolfe Research rates MDGL Outperform, a bullish rating, as of Aug 4, 2026.

When did Wolfe Research last change its view on MDGL?

On Aug 4, 2026, Wolfe Research upgrades to Outperform from Peer Perform, price target $605.

How does Wolfe Research's MDGL target compare with other analysts?

Across 5 firms with a MDGL price target in the last 12 months, the median target is $704. Wolfe Research's $605 is 14% below that.

More MDGL rating histories

• H.C. Wainwright4
• B. Riley Securities4

All Wolfe Research ratingsMDGL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.